| BML-AK518-0001 | 1 Kit | 544.00 USD | ![]() |
||
| Alternative Name: | Histone deacetylase 8 fluorescent assay kit |
| Quantity: | 96 assays |
| Kit/Set Contains: | HDAC8 (human) (recombinant) Fluor de Lys®-HDAC8 substrate and developer II Assay buffer Trichostatin A (HDAC inhibitor) White and clear 1/2-vol. 96-well plates, detailed instructions |
| Long Term Storage: | -80°C |
| Miscellaneous/General: | Although early studies suggested that HDAC8 (histone deacetylase 8) localized to the nucleus and was ubiquitously expressed, subsequent work indicates that in normal tissue it is primarily cytosolic and expressed in smooth muscle cells. However, like other class I HDACs, HDAC8 exhibits trichostatin A-inhibitable histone deacetylase activity and can mediate transcription repression. A crystal structure has been obtained for HDAC8 complexed with another, more potent inhibitor in the trichostatin class (hydroxamic acids). HDAC8 localizes to stress-fibers, along with smooth muscle a-actin and its expression appears to be essential for smooth muscle contractility. This affinity for cytoskeletal proteins may underlie HDAC8’s binding to the core binding factor ß/smooth muscle myosin heavy chain fusion protein (CBFß/SMMHC), which is created by the inversion(16) chromosomal translocation (inv(16)). CBFß/SMMHC can associate with the mSin3A corepressor and may thereby act as a dominant repressor of genes regulated by CBFß-AML1. Repression of these genes, which in the case of inv(16) would appear to be mediated by HDAC8 activity, is implicated in the genesis of acute myeloid leukemia (AML). siRNA-knockdown of HDAC8 expression has been shown to inhibit the growth of several human tumor cell lines, suggesting that HDAC8 activity may be significant in the pathogenesis of solid as well as hematologic tumors. |
| Background / Technical Information: | Please click here for the comprehensive product datasheet. |


| 17-Oct-11 | |
| Download as PDF | |
| 14-Jun-10 | |
| Download as PDF | |